Focused efforts concerning ROS1+ NSCLC patients are currently oriented towards refining the treatment scheme upon improved patient stratification, overcoming drug resistance and understanding the disease risk factors (70). The gene discussed is ROS1; the disease is non-small cell lung carcinoma.